More results...
Pascal Soriot says cost-effectiveness thresholds for new medicines have not changed for two decadesBusiness live – latest updatesThe boss of AstraZeneca has said that unless the UK ramps up spending on new drugs, it could be on a trajectory to only bei…
UK’s biggest drugmaker to put its US shares on par with its London-based stock, but says HQ will stay in CambridgeGSK’s Emma Walmsley to be replaced as CEOBusiness live – latest updatesThe UK’s biggest drugmaker, AstraZeneca, has said it will list its …
Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investmentThe UK is determined to resolve its standoff with the pharmaceutical industry and reverse a 10-year decline in NHS spending on medicines, the science ministe…
Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceedingThe drugmaker AstraZeneca has paused a planned £200m expansion of its Cambridge research site, completing a depressing week for the UK pharmaceutical i…
President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to USShares in European pharmaceutical companies have sunk to a four-month low, after Donald Trump repeated his threats to introduce tar…
Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the AtlanticAstraZeneca’s chief executive has hailed the “vital importance of the US” to the British drugmaker, days after announcing a $50bn (£37…
UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around USBusiness live – latest updatesAstraZeneca has announced it will invest $50bn (£37bn) in the US by 2030, the latest in a string of pledges by pharmaceu…
UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal SoriotBusiness live – latest updatesAstraZeneca said it was shifting the production of some medicines sold in the US from Europe to the…
The boss’s bonus is an annual debating point at Britain’s biggest company. But that’s not the only issue this yearAstraZeneca is used to facing protests over pay at its annual general meetings, given the position of its chief executive, Pascal Soriot, …
Pharma company will invest money over five years in ‘strategic partnership’ after ditching UK expansionBusiness live – latest updatesAstraZeneca will invest $2.5bn (£1.9bn) in research and manufacturing in Beijing, as the pharmaceutical company tries t…